Volver al Panel








Eli Lilly and Company (LLY)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
LLY Intraday
No data available
SímboloLLY
Fecha de SalidaJun 1, 1972
CEOMr. David A. Ricks
Empleados a Tiempo Completo50k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited States
BolsaNYSE
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | -0.21% | -2.79 US$ |
| 5 Días | -6.59% | -95.17 US$ |
| 1 Mes | +6.11% | +77.58 US$ |
| 6 Meses | +26.60% | +283.33 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de LLY...
Estadísticas Clave
Cap. de Mercado
1.20T
Relación P/E
43.85
Rend. de Div.
0.51%
Máx. 52 Semanas
$1475.25
Mín. 52 Semanas
$850.51
Consenso de Analistas
CONSENSOCompra
ALCISTA2580.6%
NEUTRAL412.9%
BAJISTA26.5%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$940.00
$940.00
Objetivo Máx.
$1700.00
$1700.00
Actual$1348.33
Objetivo Prom.$1470.06
Recomendaciones de Analistas
Precio Objetivo:$1470.06($940.00 - $1700.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre LLY
Únase a la comunidad para compartir su análisis
Últimas Noticias para LLY

Eli Lilly (LLY) After ObesityWeek Is The Stock Still Undervalued
Simply Wall St.•20 nov 2026, 20:13

What Does Eli Lilly Offer That Merck Does Not?
Trefis•20 nov 2026, 16:59

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
Motley Fool•20 nov 2026, 16:20
A $4.7 Billion Fund Just Bought These 3 Stocks
TIKR•20 nov 2026, 14:58

Cathie Wood Sold Nvidia and Bought $78 Million of Anthropic at IPO
24/7 Wall St.•20 nov 2026, 14:52

Should You Buy Bristol Myers Squibb Stock At Today's Discount?
Trefis•20 nov 2026, 14:51

Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
Zacks•20 nov 2026, 14:39

Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Reuters•20 nov 2026, 11:09
iShares U.S. Healthcare ETF (IYH) Sells $17.4 Million of Eli Lilly on Wednesday
GuruFocus.com•20 nov 2026, 11:05
Invesco S&P 500 Equal Weight (RSP) Sells $0.4 Million of NVR on Nov. 18
GuruFocus.com•20 nov 2026, 11:05